Semaglutide Research Peptide – 99%+ Pure

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same lab, same batch, same verified purity — scaled to whatever your research needs.

GLP1-RC-SM Batch Verification

Each released GLP1-RC-SM batch is independently analysed for chemical purity and identity, with the applicable laboratory report linked to the product batch.

New-U GLP1-RC-SM batch evidence

Catalogue identifier: GLP1-RC-SM

Batch number, vial count and declared mass per vial

RP-HPLC purity result for the released batch

Mass-spectrometry identity result for the released batch

Independent testing laboratory, report number and test date

Batch-linked Certificate of Analysis at /coa/semaglutide

Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Published scientific literature

External experimental and clinical studies

Receptor pharmacology and pharmacokinetics

Protocol-defined trial endpoints and timepoints

Adverse events recorded by investigators

Registered trial records and peer-reviewed citations (DOI / PMID / NCT)

Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-SM research material.

Published Research Areas

Published studies examine receptor activity, pharmacokinetics and protocol-defined metabolic, glycaemic, cardiovascular and renal endpoints. The summaries below report what investigators measured in those external studies and are not use instructions for the research material supplied here.

Receptor Pharmacology

GLP-1R agonism at pancreatic, gastrointestinal and hypothalamic sites, characterised in published receptor studies.

Metabolic Endpoints

Protocol-defined change from baseline in body mass, measured across the STEP programme.

Glycaemic Endpoints

HbA1c as a protocol-defined endpoint, measured across the SUSTAIN diabetes programme.

Cardiovascular & Renal Endpoints

Major adverse cardiovascular events (SELECT) and kidney-disease events (FLOW), measured in randomised outcome trials.

Pharmacokinetics

Systemic exposure, bioavailability and apparent half-life, from published pharmacokinetic characterisation.

Overview

In short: GLP1-RC-SM is a GLP-1R agonist research compound, commonly referred to as “Sema” in research communities.

Key research facts

Receptor pharmacology: GLP-1R agonist activity characterised in published in-vitro and clinical pharmacology studies

31-amino-acid peptide with 94% sequence homology to native human GLP-1(7-37)

Aib8 substitution investigated for DPP-IV resistance; Arg34 substitution investigated for altered peptide stability

C18 fatty-diacid/mini-PEG modification investigated as a contributor to prolonged systemic exposure (~7-day apparent half-life)

STEP-1 RCT (NEJM 2021, PMID 33567185), 2.4 mg arm: investigators reported −14.9% mean change from baseline in body weight at week 68

These points summarise lab themes, not human outcomes.

Published work characterises the receptor pharmacology, structural modifications and pharmacokinetic profile of this compound class, alongside protocol-defined endpoints investigated across registered clinical programmes.

New-U batch verification and external literature are separate evidence sets: batch testing establishes analytical identity and purity for the tested material; published studies describe their own investigational materials and protocols.

Read the full scientific overview

Molecular Architecture

A 31-amino-acid peptide sharing 94% of its sequence with native human GLP-1, a gut hormone released after meals.

Receptor Pharmacology

Receptor-pharmacology studies characterise GLP-1R agonism with glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and hypothalamic appetite-circuit signalling. Full pathway table: Receptor Pharmacology below.

Structural Modifications

Native GLP-1 is reported to be degraded within about two minutes in vivo. Published structural work attributes the prolonged systemic exposure of this compound to three engineered modifications — an Aib8 substitution, an Arg34 substitution and a Lys26-linked C18 fatty diacid investigated as an albumin-binding contributor.

Published Pharmacokinetics

Apparent elimination half-life is reported at approximately 7 days with roughly 89% subcutaneous bioavailability. Full profile: Pharmacokinetics below.

Clinical Research

Published findings summarised on this page relate to external clinical studies of the reference medicine and their respective materials and protocols. They do not establish the safety, efficacy or clinical equivalence of New-U GLP1-RC-SM material.

Primary References

Peer-reviewed publications and registered trial records are listed in full, with DOI/PMID/NCT identifiers, in Source References below.

Receptor Pharmacology

Published experimental work characterises GLP-1R agonist activity, with an albumin-binding structural modification investigated as a contributor to prolonged systemic exposure.

Pathway Effect Why it matters GLP-1R (pancreatic β-cells) Agonist activity characterised in receptor pharmacology studies Glucose-dependent insulin secretion is the defining incretin property recorded in the literature GLP-1R (pancreatic α-cells) Agonist activity characterised experimentally Glucagon suppression recorded as a measured pharmacodynamic endpoint GLP-1R (gastrointestinal tract) Agonist activity characterised experimentally Delayed gastric emptying recorded as a measured pharmacodynamic endpoint GLP-1R (hypothalamus) POMC/CART activation and AgRP/NPY inhibition characterised in preclinical models The central signalling arm measured in energy-intake studies Albumin-binding modification C18 fatty diacid via a γGlu/mini-PEG spacer; >99% plasma protein binding reported Investigated as a contributor to prolonged systemic exposure (~7-day apparent half-life) Proteolytic stability Aib8 and Arg34 substitutions Structural modifications investigated for altered peptide stability against DPP-IV

Deeper dive for scientific readers

Lau et al. (J Med Chem, 2015; DOI 10.1021/acs.jmedchem.5b00726) describe three modifications relative to native GLP-1(7-37): an Aib substitution at position 8, an Arg substitution at position 34, and Lys26 acylation with a C18 fatty diacid via a γGlu/mini-PEG (AEEA) spacer. The fatty chain is reported to bind serum albumin reversibly, which the authors attribute the extended circulating exposure to. Published pharmacokinetic work reports steady-state exposure after 4–5 weeks of the protocol-defined weekly administration, with elimination via proteolytic cleavage and β-oxidation of the fatty chain and no CYP-mediated interactions. Every figure here is an observation recorded in the cited external study of the reference medicine.

Common Questions People Are Asking

What is Semaglutide in scientific research?

Semaglutide is a 31-amino-acid GLP-1 receptor agonist characterised in published receptor-pharmacology and clinical research. It is approved as a medicine in some jurisdictions under other manufacturers' brand names; the material supplied here is not that finished pharmaceutical.

What is GLP1-RC-SM?

GLP1-RC-SM is New-U's catalogue identifier for the laboratory research material offered through this research profile. It is not a medicine, a treatment, a generic pharmaceutical or a therapeutic product, it is not equivalent to any clinical or commercial product, and it is not offered for human or veterinary use.

Which receptor systems are examined in Semaglutide research?

Published work characterises agonist activity at the GLP-1 receptor across four tissue contexts: pancreatic β-cells (glucose-dependent insulin secretion), pancreatic α-cells (glucagon suppression), the gastrointestinal tract (delayed gastric emptying) and hypothalamic circuits (POMC/CART activation, AgRP/NPY inhibition in preclinical models). Structural work additionally investigates the C18 fatty-diacid albumin-binding modification and the Aib8 substitution for altered proteolytic stability.

What analytical testing accompanies GLP1-RC-SM?

Each released GLP1-RC-SM batch is tested by an independent analytical laboratory for purity by RP-HPLC area normalisation and for identity by mass spectrometry, and the result is published as a batch-linked Certificate of Analysis recording the laboratory, report number, measured purity and test date. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Where can I view the current batch COA for GLP1-RC-SM?

The current batch certificate — laboratory, report number, measured purity and test date — is published at /coa/semaglutide, together with the testing history for the compound.

What does >99% HPLC purity mean?

It is a purity figure obtained by reversed-phase high-performance liquid chromatography using area normalisation: the target peak accounts for more than 99% of the total integrated peak area in the chromatogram for the tested sample. It is a statement about chemical purity of that sample only, and says nothing about sterility, endotoxin content, pharmaceutical equivalence or any clinical property.

What clinical trials are referenced on this page?

Five external studies of the reference medicine: STEP-1 (Wilding et al., NEJM 2021; PMID 33567185), SELECT (Lincoff et al., NEJM 2023; PMID 37952131), FLOW (Perkovic et al., NEJM 2024; DOI 10.1056/NEJMoa2403347), SOUL (McGuire et al., NEJM 2025; DOI 10.1056/NEJMoa2501006) and the structural paper by Lau et al. (J Med Chem 2015). Each reported result on this page is attributed to its study, arm and timepoint.

How is published clinical research distinguished from New-U batch testing?

They are separate bodies of evidence. Published clinical research is external work on the approved finished pharmaceutical, conducted under those studies' own protocols; it establishes nothing about the material supplied here. New-U batch testing is analytical work on the GLP1-RC-SM lot itself — RP-HPLC purity and mass-spectrometry identity — and it establishes nothing clinical. A certificate of analysis combined with an external clinical paper does not amount to clinical validation of GLP1-RC-SM.

Is GLP1-RC-SM the same as an approved branded medicine?

No. Approved branded semaglutide products are prescription, sterile finished pharmaceuticals manufactured under cGMP by their marketing authorisation holders. GLP1-RC-SM is unapproved laboratory research material supplied as a lyophilised powder. It is not equivalent to, a generic of, or a substitute for any approved product.

How is Semaglutide different from native GLP-1?

Published structural work describes 94% sequence homology with native human GLP-1(7-37) plus three engineered modifications: an Aib substitution at position 8 investigated for DPP-IV resistance, an Arg substitution at position 34, and a C18 fatty diacid attached at Lys26. The fatty acid is reported to bind albumin, which the literature attributes the extension of apparent half-life from roughly 2 minutes to approximately 7 days to.

What form is GLP1-RC-SM supplied in?

GLP1-RC-SM is supplied as a lyophilised powder in sealed vials, in sealed 10-vial research packs across the listed strengths, with a batch-linked Certificate of Analysis.

How should laboratory research material be stored?

Store the lyophilised powder in a freezer at −20 °C. If a laboratory protocol requires the material in solution, hold the resulting solution refrigerated at 1–6 °C, protected from light, and avoid repeated warming and cooling cycles, which can degrade the fatty-acid modification. Storage conditions are laboratory handling information only.

Is Semaglutide research compared head-to-head with Tirzepatide research?

One published trial, SURMOUNT-5 (NEJM 2025), was designed as a head-to-head comparison and reported a larger mean change from baseline in body weight in the tirzepatide arm than the semaglutide arm at week 72 (−20.2% vs −13.7%). Results from separate trials of the two compounds are not head-to-head comparisons and the study designs do not support treating them as such.

Is it legal to buy Semaglutide?

In the United States, Semaglutide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Half-life Apparent elimination half-life reported at approximately 7 days (165–184 h); steady-state exposure reported after 4–5 weeks Absorption route Study protocols used subcutaneous administration (~89% reported bioavailability); a SNAC-enhanced oral tablet formulation is also described in the literature (~0.4–1% reported oral bioavailability) Bioavailability ~89% subcutaneous; 0.4–1% oral (SNAC co-formulation) reported Metabolism / clearance Proteolytic cleavage of the peptide backbone plus β-oxidation of the C18 fatty-diacid chain reported; no CYP-mediated interactions; ~3% reported excreted unchanged in urine Stability Laboratory handling — lyophilised: −20 °C. Reconstituted: 1–6 °C, protect from light; avoid repeated freeze–thaw Notes Reported volume of distribution ~12.5 L; >99% albumin-bound; clearance ~0.035 L/h. The reversible C18 fatty-diacid/albumin interaction is the protraction mechanism described in the published pharmacokinetic literature. These are observations from external studies of the reference medicine, not a handling or administration instruction for research material.

Research-Observed Effects

STEP-1 RCT (Wilding et al., NEJM 2021; PMID 33567185), overweight/obesity population, 2.4 mg arm: investigators reported a mean change from baseline in body weight of −14.9% at week 68 vs −2.4% on placebo

SELECT RCT (Lincoff et al., NEJM 2023; PMID 37952131), 17,604 participants with overweight/obesity and established cardiovascular disease without diabetes: investigators reported a 20% relative reduction in major adverse cardiovascular events

FLOW RCT (Perkovic et al., NEJM 2024): investigators reported a 24% relative reduction in major kidney-disease events in a type 2 diabetes CKD population

SOUL RCT (McGuire et al., NEJM 2025), oral (SNAC) formulation in high-risk type 2 diabetes: investigators reported a 14% relative reduction in major adverse cardiovascular events

SUSTAIN programme: investigators reported HbA1c reductions of ~1.5–1.8% as a protocol-defined endpoint, with a low reported hypoglycaemia rate attributed to glucose-dependent insulin release

Pharmacodynamic studies recorded delayed gastric emptying and reduced postprandial glucose excursions as measured endpoints

Published Research Context

Registered clinical research of the reference medicine used protocol-defined intervention arms. The STEP weight-management programme included arms from 0.25 mg up to a 2.4 mg maintenance level, with a protocol-defined step-up period of roughly 16 weeks; the SUSTAIN diabetes programme used 0.5–2.0 mg arms. Study protocols used once-weekly subcutaneous administration.

These figures are characteristics of external clinical trials of an approved medicine. They are recorded here as scientific study context and are not a protocol, schedule, starting point or instruction for any use of laboratory research material.

Adverse Events Reported in Published Clinical Research

The events below were recorded by investigators in published clinical trials of the reference medicine. They describe what was observed in those study populations under those protocols; they are not a prediction of, or guidance about, anything a reader may experience.

Common

Nausea — reported as the most frequent event, described as escalation-related and typically transient

Diarrhoea

Vomiting

Constipation

Abdominal pain and decreased appetite recorded as reported adverse events

Rare

Gallbladder events (cholelithiasis, cholecystitis)

Acute pancreatitis, reported infrequently

Injection-site reactions recorded under the study protocols

Thyroid C-cell tumours observed in rodent studies — the basis of the reference medicine’s boxed warning; human relevance reported as unconfirmed

Dose-dependent

Investigators reported gastrointestinal events scaling with arm level and during the protocol-defined step-up period, attenuating at steady state

A transient resting-heart-rate increase of a few bpm was recorded as a measured endpoint

Evidence Tier

Overall: Tier 1: Human clinical

The evidence tier describes the published literature on Semaglutide, the scientific subject, and specifically on the finished pharmaceutical studied in those trials. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-SM research material.

Tier 1 · Human clinical

STEP-1 weight-management RCT — −14.9% mean change from baseline in body weight at week 68 (NEJM 2021; PMID 33567185)

SELECT cardiovascular-outcomes RCT — 17,604 participants (NEJM 2023; PMID 37952131)

FLOW kidney-outcomes RCT (NEJM 2024); SOUL oral cardiovascular-outcomes RCT (NEJM 2025); SUSTAIN diabetes programme

Certificates, databases & peer-reviewed sources

Last reviewed: 14 August 2026 · New-U Research Compounds

Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. · 2021 · PMID: 33567185 · DOI: 10.1056/NEJMoa2032183

Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. · 2023 · PMID: 37952131 · DOI: 10.1056/NEJMoa2307563

Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Type 2 Diabetes (FLOW). N Engl J Med. · 2024 · DOI: 10.1056/NEJMoa2403347

McGuire DK et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL). N Engl J Med. · 2025 · DOI: 10.1056/NEJMoa2501006

Lau J et al. Discovery of the Once-Weekly GLP-1 Analogue Semaglutide. J Med Chem. · 2015 · DOI: 10.1021/acs.jmedchem.5b00726

PubMed: peer-reviewed literature on Semaglutide

ClinicalTrials.gov: registered studies on Semaglutide

Semaglutide: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

31-amino-acid peptide, 94% homologous to native human GLP-1(7-37)

GLP-1R agonist activity characterised in receptor-pharmacology studies

Aib8 substitution investigated for DPP-IV resistance

C18 fatty-diacid modification reported to give >99% albumin binding

Apparent elimination half-life reported at approximately 7 days in published pharmacokinetic research

GLP1-RC-SM laboratory research material — analytically verified, >99% HPLC purity

Supplied as lyophilised powder for laboratory research; not the finished pharmaceutical studied in the cited trials

Specifications

New-U catalogue identifier GLP1-RC-SM Scientific subject Semaglutide Molecular Formula C₁₈₇H₂₉₁N₄₅O₅₉ Molecular Weight 4113.58 Da Receptor characterised GLP-1 receptor (class B GPCR) Purity (analytical) >99% by RP-HPLC area normalisation Identity (analytical) Confirmed by mass spectrometry on the released batch Form Lyophilised powder Published half-life Approximately 7 days, 165-184 h (external pharmacokinetic research) Storage Lyophilised: −20 °C freezer. Reconstituted: 1-6 °C, away from light. Intended use Laboratory research material. Not for human or veterinary use.

Semaglutide Research — GLP1-RC-SM Laboratory Research Material

Semaglutide is among the most extensively characterised metabolic peptides in the published literature, and the GLP-1 receptor agonist against which later compounds such as tirzepatide and the CagriSema co-formulation are benchmarked in the research record. Published structural work describes how a hormone degraded within minutes in vivo was engineered for prolonged systemic exposure by anchoring it to serum albumin via a C18 fatty-diacid modification.

Published clinical research of the reference medicine reports protocol-defined endpoints: a mean change from baseline in body weight of −14.9% at week 68 in the STEP-1 2.4 mg arm (NEJM 2021), a 20% relative reduction in major adverse cardiovascular events in SELECT (NEJM 2023), a 24% relative reduction in major kidney-disease events in FLOW (NEJM 2024), and a 14% relative reduction in major adverse cardiovascular events with the oral SNAC formulation in SOUL (NEJM 2025). Each of those figures belongs to the study, population and timepoint that produced it.

New-U Research Compounds supplies GLP1-RC-SM as lyophilised, analytically verified laboratory research material at >99% HPLC purity, with identity and purity confirmed by independent laboratories. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-SM research material. GLP1-RC-SM is not an approved medicine, is not the finished pharmaceutical studied in the cited trials, and is not offered for human or veterinary use.

Glucagon-like peptide-1 - Wikipedia

GLP-1 receptor agonist - Wikipedia

Customer Reviews

No customer reviews yet - be the first to share your experience.

More in Metabolic Research

Semaglutide vs related Metabolic Research compounds

Compound Price Purity spec COA Semaglutide from $150 >99% HPLC 1 published batch Retatrutide from $200 >99% HPLC 4 published batches Tirzepatide from $160 >99% HPLC 2 published batches

Semaglutide vs Retatrutide - full comparison

Semaglutide vs Tirzepatide - full comparison

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Semaglutide

Semaglutide research guide

Buy Semaglutide - pricing & packs

Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research